Skip to main content

Table 1 Patients’ characteristics and clinical symptoms

From: The clinical features of pulmonary artery involvement in Takayasu arteritis and its relationship with ischemic heart diseases and infection

  PAI (n = 24) Without PAI (n = 142) P value
Patients’ characteristics
 Duration from onset (years) 20.7 ± 14.6 21.4 ± 15.6 0.835
 Observation period (years) 7.8 ± 6.8 9.1 ± 6.8 0.355
 Onset age 33.5 ± 13.1 30.1 ± 15.8 0.325
 Age at surveillance 54.5 ± 17.0 52.2 ± 17.7 0.564
 Female 22 (91.7%) 130 (91.6%) 1.000
Symptoms
Systemic manifestation
 Fever 2 (9.5%) 33 (25.8%) 0.163
 General fatigue 7 (33.3%) 54 (42.5%) 0.481
 Hypertension 8 (38.1%) 53 (40.8%) 1.000
Head and neck
 Dizziness 8 (38.1%) 48 (37.2%) 1.000
 Headache 7 (33.3%) 36 (27.9%) 0.610
 Syncope 0 (0.0%) 8 (6.3%) 0.602
Eyes
 Eye symptoms 4 (20.0%) 26 (20.5%) 1.000
 Visual disorder 2 (9.5%) 13 (10.1%) 1.000
Heart and lung
 Dyspnea 5 (25.0%) 11 (8.6%) 0.044
 Chest compression 6 (30.0%) 16 (12.5%) 0.082
 Hemosputum 1 (4.8%) 2 (1.6%) 0.368
 Heart murmur 8 (40.0%) 40 (31.8%) 0.455
 Ischemic heart disease 6 (28.6%) 12 (9.2%) 0.022
 Aortic valve regurgitation 12 (57.1%) 55 (41.3%) 0.236
 PAH 4 (16.7%) 0 (0.0%) <0.001
Upper limbs
 Pulselessness 5 (23.8%) 31 (24.6%) 1.000
 BP discrepancies between arms 5 (25.0%) 44 (34.1%) 0.610
 Fatigue of upper limbs 5 (25.0%) 41 (32.3%) 0.611
Aorta
 Aortic aneurysm 1 (4.8%) 14 (10.9%) 0.696
Kidney
 Renal artery stenosis 0 (0.0%) 22 (18.5%) 0.043
 Renal disorder 2 (9.5%) 18 (13.9%) 0.741
Infection
 Serious infection 7 (29.2%) 17 (12.7%) 0.059
 Respiratory infection 6 (25.0%) 8 (6.0%) 0.009
 Nontuberculous mycobacterium 5 (20.8%) 1 (0.8%) <0.001
Treatment
 Glucocorticoid 21 (87.5%) 110 (77.5%) 0.416
 Maximum glucocortioid (PSL) 31.1 ± 3.2 33.4 ± 1.4 0.508
 Immunosuppressants 6 (26.1%) 54 (38.9%) 0.351
 Biologics 5 (22.7%) 17 (12.2%) 0.206
 GC only 11 (47.8%) 55 (39.6%) 0.455
 GC + IS 3 (12.5%) 37 (26.1%) 0.200
 GC + biologics 2 (8.7%) 1 (0.7%) 0.009
 GC + IS + biologics 3 (13.0%) 15 (10.8%) 0.750
 Antiplatelet therapy 11 (52.4%) 86 (68.8%) 0.210
 Anticoagulation therapy 8 (38.1%) 21 (17.1%) 0.038
 Cardiovascular surgery 2 (11.1%) 33 (25.8%) 0.242
 Catheter treatment 3 (15.8%) 25 (21.2%) 0.764
  1. Data are expressed as mean ± SD, or number (percentage). The difference of continuous variables was tested by Student’s t test, and that of qualitative variables was tested by Fisher’s exact test. PAI pulmonary artery involvement, PAH pulmonary arterial hypertension, BP blood pressure, PSL predonisolone (mg/day), GC glucocorticoid, IS immunosuppressants. The percentage is calculated as a ratio of the number of cases for which clinical information was available